SYGMA 1
2018
Symbicort Given As Needed in Mild Asthma 1
In 3,849 patients with mild asthma, PRN budesonide-formoterol reduced severe exacerbations compared with PRN terbutaline.
Result
Efficacy: Well-controlled asthma weeksOR 1.14 (95% CI 1.00-1.30) · P = 0.046
Below 1 favours PRN terbutaline, above 1 favours PRN budesonide-formoterol.
- Absolute difference
- 3.3 points
The absolute difference is derived from the event rates.
Also reported: Severe exacerbation rate reduced 64% vs as-needed SABA (RR 0.36, 95% CI 0.27–0.49).
- Subtopic
- PRN ICS-formoterol
- Design
- Multicentre RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- GINA 2021 Asthma
- Source
- O'Byrne PM, et al. N Engl J Med. 2018;378(20):1865-1876.doi 10.1056/NEJMoa1715274
Discussion & critique
Foundational evidence for GINA's recommendation against SABA-only therapy; PRN ICS-formoterol is the new standard for mild asthma.